Fresenius Medical Care AG & Co. has agreed to acquire home dialysis specialist Nxstage Medical Inc. for about $2 billion in a deal expected to close next year. The Bad Homburg, Germany-based company will offer $30 per share to acquire all of Nxstage's outstanding shares. This represents a 22 percent premium to Boston-based Nxstage's 90-day moving average share price.